141 related articles for article (PubMed ID: 33337372)
41. Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort.
Gallet Q; Bouteloup V; Locatelli M; Habert MO; Chupin M; Delrieu J; Lebouvier T; Robert G; David R; Bulteau S; Balageas AC; Surget A; Belzung C; Arlicot N; Ribeiro MJ; Barantin L; Andersson F; Cottier JP; Gissot V; El-Hage W; Camus V; Gohier B; Desmidt T;
Neuropsychopharmacology; 2022 Apr; 47(5):1114-1120. PubMed ID: 34893757
[TBL] [Abstract][Full Text] [Related]
42. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
43. TDP-43 is a key player in the clinical features associated with Alzheimer's disease.
Josephs KA; Whitwell JL; Weigand SD; Murray ME; Tosakulwong N; Liesinger AM; Petrucelli L; Senjem ML; Knopman DS; Boeve BF; Ivnik RJ; Smith GE; Jack CR; Parisi JE; Petersen RC; Dickson DW
Acta Neuropathol; 2014; 127(6):811-24. PubMed ID: 24659241
[TBL] [Abstract][Full Text] [Related]
44. Altered whole-brain white matter networks in preclinical Alzheimer's disease.
Fischer FU; Wolf D; Scheurich A; Fellgiebel A;
Neuroimage Clin; 2015; 8():660-6. PubMed ID: 26288751
[TBL] [Abstract][Full Text] [Related]
45. Financial Management Skills in Aging, MCI and Dementia: Cross Sectional Relationship to 18F-Florbetapir PET Cortical β-amyloid Deposition.
Tolbert S; Liu Y; Hellegers C; Petrella JR; Weiner MW; Wong TZ; Murali Doraiswamy P
J Prev Alzheimers Dis; 2019; 6(4):274-282. PubMed ID: 31686100
[TBL] [Abstract][Full Text] [Related]
46. Progress of Brain Amyloid Deposition in Familial Alzheimer's Disease with Taiwan D678H APP Mutation.
Weng YC; Hsiao IT; Huang CY; Huang KL; Liu CH; Chang TY; Yen TC; Lin KJ; Huang CC
J Alzheimers Dis; 2018; 66(2):775-787. PubMed ID: 30320594
[TBL] [Abstract][Full Text] [Related]
47. TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease.
Shih YH; Tu LH; Chang TY; Ganesan K; Chang WW; Chang PS; Fang YS; Lin YT; Jin LW; Chen YR
Nat Commun; 2020 Nov; 11(1):5950. PubMed ID: 33230138
[TBL] [Abstract][Full Text] [Related]
48. Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease.
Trzepacz PT; Hochstetler H; Yu P; Castelluccio P; Witte MM; Dell'Agnello G; Degenhardt EK;
Dement Geriatr Cogn Disord; 2016; 41(1-2):68-79. PubMed ID: 26625159
[TBL] [Abstract][Full Text] [Related]
49. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
Joshi AD; Pontecorvo MJ; Clark CM; Carpenter AP; Jennings DL; Sadowsky CH; Adler LP; Kovnat KD; Seibyl JP; Arora A; Saha K; Burns JD; Lowrey MJ; Mintun MA; Skovronsky DM;
J Nucl Med; 2012 Mar; 53(3):378-84. PubMed ID: 22331215
[TBL] [Abstract][Full Text] [Related]
50. Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43.
Wennberg AM; Tosakulwong N; Lesnick TG; Murray ME; Whitwell JL; Liesinger AM; Petrucelli L; Boeve BF; Parisi JE; Knopman DS; Petersen RC; Dickson DW; Josephs KA
JAMA Neurol; 2018 Nov; 75(11):1347-1354. PubMed ID: 30422173
[TBL] [Abstract][Full Text] [Related]
51. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
Dugger BN; Clark CM; Serrano G; Mariner M; Bedell BJ; Coleman RE; Doraiswamy PM; Lu M; Fleisher AS; Reiman EM; Sabbagh MN; Sadowsky CH; Schneider JA; Zehntner SP; Carpenter AP; Joshi AD; Mintun MA; Pontecorvo MJ; Skovronsky DM; Sue LI; Beach TG
J Neuropathol Exp Neurol; 2014 Jan; 73(1):72-80. PubMed ID: 24335535
[TBL] [Abstract][Full Text] [Related]
52. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
53. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
55. Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues.
Leuzy A; Zimmer ER; Heurling K; Rosa-Neto P; Gauthier S
Amyloid; 2014 Sep; 21(3):143-8. PubMed ID: 24919109
[TBL] [Abstract][Full Text] [Related]
56. Regional brain hypometabolism is unrelated to regional amyloid plaque burden.
Altmann A; Ng B; Landau SM; Jagust WJ; Greicius MD;
Brain; 2015 Dec; 138(Pt 12):3734-46. PubMed ID: 26419799
[TBL] [Abstract][Full Text] [Related]
57. TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnestic Alzheimer's Disease Dementia.
Sahoo A; Bejanin A; Murray ME; Tosakulwong N; Weigand SD; Serie AM; Senjem ML; Machulda MM; Parisi JE; Boeve BF; Knopman DS; Petersen RC; Dickson DW; Whitwell JL; Josephs KA
J Alzheimers Dis; 2018; 64(4):1227-1233. PubMed ID: 30010126
[TBL] [Abstract][Full Text] [Related]
58. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
[TBL] [Abstract][Full Text] [Related]
59. Neuropathologic Features of Antemortem Atrophy-Based Subtypes of Alzheimer Disease.
Mohanty R; Ferreira D; Frerich S; Muehlboeck JS; Grothe MJ; Westman E;
Neurology; 2022 Jul; 99(4):e323-e333. PubMed ID: 35609990
[TBL] [Abstract][Full Text] [Related]
60. TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease.
Carlos AF; Tosakulwong N; Weigand SD; Senjem ML; Schwarz CG; Knopman DS; Boeve BF; Petersen RC; Nguyen AT; Reichard RR; Dickson DW; Jack CR; Lowe V; Whitwell JL; Josephs KA
Alzheimers Dement; 2023 Jun; 19(6):2343-2354. PubMed ID: 36463537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
